Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response. Alimentary pharmacology & therapeutics Park, J. E., Nguyen, V. H., Tsai, P. C., Toyoda, H., Leong, J., Guy, J. E., Yeh, M. L., Huang, C. F., Yasuda, S., Abe, H., Hsu, Y. C., Tseng, C. H., Liu, J., Chen, Y. L., Lin, P. Y., Jun, D. W., Yoshimaru, Y., Ogawa, E., Ishigami, M., Enomoto, M., Tamori, A., Uojima, H., Wang, X. Z., Xu, Q., Takahashi, H., Eguchi, Y., Inoue, K., Huang, D. Q., Zhao, W. J., Chuang, W. L., Dai, C. Y., Huang, J. F., Barnett, S., Maeda, M., Cheung, R., Landis, C., Tanaka, Y., Roberts, L. R., Schwartz, M. E., Kumada, T., Yu, M. L., Nguyen, M. H. 2024

Abstract

Racial and ethnic disparities exist for hepatitis C virus (HCV) treatment and hepatocellular carcinoma (HCC) survival.To evaluate the impact of HCV treatment on such disparities.In a retrospective cohort study, we analysed 6069 patients with HCV-related HCC (54.2% Asian, 30.1% White, 8.5% Black, and 7.3% Hispanic) from centres in the United States and Asia.The mean age was 61, 60, 59 and 68, respectively, for White, Black, Hispanic and Asian patients. Black patients were most likely to have Barcelona Clinic Liver Cancer stage D, vascular invasion and distant metastasis (23% vs. 5%-15%, 20% vs. 10%-17% and 10% vs. 5%-7%, respectively; all p?

View details for DOI 10.1111/apt.17863

View details for PubMedID 38173278